Description
Gene Therapy for Cancer Market Overview
The global gene therapy for cancer market was valued at approximately USD 3.44 billion in 2024, is projected to reach around USD 4.14 billion in 2025, and is expected to grow to about USD 19.97 billion by 2034, exhibiting a Compound Annual Growth Rate (CAGR) of 19.23% from 2025 to 2034.
The global market for gene therapy in the treatment of cancer is rapidly expanding, driven by advances in biotechnology and the increasing demand for personalized medicine. According to recent studies, the market is projected to reach billions of dollars in the coming years, as more and more pharmaceutical companies invest in research and development in this cutting-edge field. With the potential to revolutionize cancer treatment, gene therapy offers a new approach to targeting and eliminating cancer cells at the molecular level.
One of the key drivers of the market growth is the increasing prevalence of cancer worldwide, leading to a growing need for more effective and targeted treatment options. Gene therapy holds the promise of personalized medicine, where treatments are tailored to individual patients based on their genetic makeup. This personalized approach not only improves treatment outcomes but also reduces the risk of adverse side effects often associated with traditional cancer therapies.
Gene therapy for cancer offers several potential benefits over conventional treatments, including targeted therapy, reduced toxicity, and the potential for long-term remission. By targeting specific genes or proteins involved in cancer growth, gene therapy can effectively destroy cancer cells while minimizing damage to healthy tissues. This targeted approach not only increases treatment efficacy but also reduces the risk of harmful side effects commonly experienced with chemotherapy and radiation therapy.
Gene Therapy for Cancer Market Dynamics
Drivers
One of the key drivers of the gene therapy for cancer market is the growing prevalence of cancer worldwide. As the number of cancer cases continues to rise, there is an urgent need for more effective and targeted treatments. Gene therapy offers a promising solution by targeting the specific genetic mutations that drive cancer growth.
Additionally, advancements in gene editing technologies, such as CRISPR-Cas9, have greatly improved the precision and efficiency of gene therapy. This has led to a surge in research and development activities focused on harnessing these technologies for the treatment of cancer.
Restraints
Despite the promising potential of gene therapy for cancer, there are several challenges that need to be overcome. One of the main restraints is the high cost of developing and manufacturing gene therapies. This can limit access to these treatments for patients who may benefit from them, especially in developing countries.
Another challenge is the potential for off-target effects, where the gene therapy may inadvertently affect healthy cells. This can lead to unforeseen complications and side effects, making it crucial to carefully design and test these therapies before they can be used in clinical settings.
Challenges
One of the biggest challenges facing the gene therapy for cancer market is regulatory approval. Due to the innovative nature of these treatments, regulatory agencies around the world are navigating how to evaluate and approve gene therapies in a timely and safe manner. This can lead to delays in bringing these treatments to market, impacting patients who are in urgent need of new treatment options.
Another challenge is the skepticism and uncertainty surrounding gene therapy among patients and healthcare providers. There is still a lack of awareness and understanding about how gene therapy works and its potential benefits. Educating the public and building trust in these treatments will be essential for driving adoption and acceptance.
Opportunities
Despite these challenges, the gene therapy for cancer market presents significant opportunities for growth and innovation. With continued advancements in gene editing technologies and a growing understanding of the underlying genetic drivers of cancer, researchers are exploring new avenues for targeted and personalized treatments.
Additionally, collaborations between academia, industry, and regulatory agencies are fostering a supportive ecosystem for the development of gene therapy for cancer. This collaborative approach is accelerating the pace of research and development, bringing us closer to realizing the full potential of gene therapy in treating cancer.
List of Key Players
- Biogen
- Gilead Sciences (Kite)
- Novartis
- Adaptimmune
- Bluebird Bio
- GlaxoSmithKline
- Merck
- Celgene
- Amgen
- Spark Therapeutics
- Sarepta Therapeutics
- Orchard Therapeutics
- Transgene
- Shenzhen SibionoGenetech
- Shanghai Sunway Biotech
- Oncogenex Pharmaceuticals
- ZioPharm Oncology
- MolMed
- GenVec
- Agens, Inc.
Recent Developments:
Novartis – June 2, 2025
Announced that the Phase III PSMAddition trial of Pluvicto™ (lutetium‑177 PSMA radioligand therapy) in PSMA-positive metastatic hormone-sensitive prostate cancer met its primary endpoint, showing a statistically significant improvement in radiographic progression-free survival, with positive trends in overall survival.
Novartis – March 19, 2025
Published positive Phase III results for intrathecal onasemnogene abeparvovec (OAV101 IT) in spinal muscular atrophy, supporting a broader patient population and planning regulatory applications in the first half of 2025.
Bluebird Bio – March 2025
Bluebird Bio announced acquisition by investment firms Carlyle and SK Capital for under $30 million, reflecting the financial and commercial challenges of its lentiviral ex vivo gene therapy business despite its approved treatments.
Gene Therapy for Cancer Market Segmentation
By Therapy Type
- Gene-Induced Immunotherapy
- Oncolytic Virotherapy
- Gene Transfer Therapies
By Delivery Method
- Viral vectors
- Non-viral vectors (lipid nanoparticles, electroporation)
By Cancer Type
- Hematologic cancers (leukemia, lymphoma, multiple myeloma)
- Solid tumors (synovial sarcoma, melanoma, breast, lung, head & neck)
By End User
- Hospitals
- Cancer research & treatment centers
- Diagnostic labs
Regional Market Insights: A Breakdown by Region
North America
North America is a key player in the gene therapy market for cancer, with the U.S leading the way in research and development.
The high prevalence of cancer cases in the region has driven the demand for new and effective treatment options.
Clinical trials for gene therapy in cancer treatment are abundant in North America, showcasing the region’s commitment to innovation in healthcare.
Europe
Europe is another prominent region in the gene therapy market, with countries like Germany and the UK at the forefront of research.
The European Medicines Agency has paved the way for the approval of gene therapy treatments for cancer, providing a regulatory framework for their use.
Collaboration between academic institutions and pharmaceutical companies in Europe has accelerated the development of gene therapy for cancer.
Asia Pacific
The gene therapy market for cancer in Asia Pacific is rapidly growing, with countries like China and Japan investing heavily in research and development.
The region’s large population and increasing cancer burden are driving the demand for innovative treatment options like gene therapy.
Clinical trials in Asia Pacific are expanding, offering patients access to cutting-edge gene therapy treatments for cancer.
Target Audience
Pharmaceutical & Biotech Developers in Gene Therapy
Hospitals, Cancer Centers & Academic Medical Institutes
Gene Therapy Manufacturing CDMOs/CROs
Diagnostic and Genomic Testing Labs
Regulatory Agencies (FDA, EMA, PMDA)
Health Insurers & Payers
Investors (Venture Capital, Biotech Funds)
Patient Advocacy Organizations focused on oncology
